Aims/hypothesis The aim of this study was to evaluate the separate impact of insulin resistance and impaired glucose tolerance (IGT) on the incretin effect. Methods Twenty-one healthy glucose-tolerant first-degree relatives of patients with type 2 diabetes underwent a 75 g OGTT, an isoglycaemic i.v. glucose test and a mixed meal to evaluate the incretin effect before and after treatment with dexamethasone to increase insulin resistance. Beta cell glucose sensitivity, beta cell index and fasting proinsulin were measured as indices of beta cell function.
Introduction
'The incretin effect' is the phenomenon that oral glucose elicits a greater insulin response compared with glucose infused intravenously, giving identical plasma glucose profiles (isoglycaemia) [1] . It is mediated by two incretin hormones, glucagon-like peptide 1 (GLP-1) and glucosedependent insulinotropic polypeptide (GIP) [2] [3] [4] .
The incretin effect is markedly reduced in type 2 diabetes [5, 6] , and is diminished in individuals with impaired glucose tolerance (IGT) [7] and obesity [8] . The loss of the incretin effect is associated with a reduced insulinotropic effect of GLP-1 [9, 10] and an almost complete loss of latephase insulin secretion in response to GIP [10] . The incretin effect is also reduced in diabetes secondary to chronic pancreatitis [11] , suggesting that the impairment is secondary to the development of diabetes [11] and raising the question of when the defect becomes apparent. Prediabetes is characterised by insulin resistance [12] , and if secretion of insulin is insufficient to compensate for this, the result is IGT or frank diabetes [12] .
We examined whether the incretin effect would be affected by induction of insulin resistance and/or development of IGT in healthy individuals. We used dexamethasone as an experimental tool to mimic the insulin resistance and glucose intolerance seen in prediabetes. In a previous study [13] , shortterm dexamethasone resulted in increased insulin resistance in healthy relatives of individuals with type 2 diabetes; in addition, some participants developed glucose intolerance. By increasing insulin resistance to the same degree in all participants while inducing glucose intolerance in only some individuals, we aimed to isolate the individual impact of these two factors on the incretin effect. We examined first-degree relatives of individuals with type 2 diabetes and measured the incretin effect before and after dexamethasone [5, 14] .
We also investigated whether a reduction in the incretin effect is associated with beta cell defects. The insulin response to i.v. glucose is impaired and proinsulin processing is defective in the early stages of development of type 2 diabetes [15, 16] . Therefore, we evaluated beta cell function during the i.v. glucose test, and calculated the proinsulin/Cpeptide ratio in the fasting state as an index of beta cell dysfunction [16] . Normally, during changes in insulin sensitivity the beta cells respond with proportionate reciprocal changes in insulin secretion, thereby maintaining normal glucose tolerance (NGT) [17, 18] . Therefore, insulin secretion should be evaluated in relation to insulin resistance [19] , to detect subtle beta cell defects [20] . Finally, all participants underwent a mixed meal before and after dexamethasone in order to examine beta cell function and incretin hormone secretion during physiological stimulation.
Methods
Participants Eleven men and ten women with at least one first-degree and one second-degree relative with type 2 diabetes underwent a 75 g OGTT to ensure NGT according to WHO criteria [21, 22] . After dexamethasone, the OGTT showed that one group retained NGT (n010), while the other developed IGT (n011). There were no significant differences in baseline characteristics between the groups (Table 1 ). All participants gave oral and written consent. The study was approved by Scientific Ethics Committee D of the Capital Region of Denmark (registration number H-D-2008-087), and followed the principles of the Helsinki Declaration II (registered with Clinicaltrials.gov, registration no. NCT00784745).
Experimental design Within 7 days of the start of dexamethasone, participants were studied on three different days with OGTT, i.v. glucose and a meal. The same three tests were performed on the three consecutive days immediately following 5 days of dexamethasone, 2 mg twice daily. On days 1 and 2 after the 5 days of dexamethasone, 2 mg dexamethasone was given in the afternoon. All participants were studied after an overnight (10 h) fast. On experimental days, with participants in the recumbent position, an i.v. catheter was inserted into an antebrachial vein and the arm was wrapped in a heating blanket in order to arterialise blood samples. [23] . The contralateral arm was cannulated for glucose infusion (20% [wt/ vol.]). All participants ingested 75 g of water-free glucose dissolved in 300 ml water. Blood samples were collected as indicated in Figs 1 and 2. Blood samples PG was measured at the bedside from blood sampled in fluoride-containing tubes, and immediately centrifuged for 1 min at 7,400g at room temperature. Blood for the measurement of GLP-1, GIP and glucagon was distributed into chilled tubes containing EDTA, which were immediately placed on ice and subsequently centrifuged at 4°C for 15 min at 1,200g. Plasma was stored at −20°C, with the exception of plasma for insulin and C-peptide, which was stored at −80°C.
Analyses PG concentrations were measured by the glucose oxidase method, using a glucose analyser (2300 Stat Plus analyser; YSI, Yellow Springs, OH, USA). Plasma samples were assayed for total GLP-1 as previously described [24] , using a radioimmunoassay with antiserum specific for the C-terminal of the GLP-1 molecule (antiserum 89390, produced in house), which therefore reacts equally with intact GLP-1 and the primary (N-terminally truncated) metabolite. Total GIP was measured using the C-terminally directed antiserum R65, produced in house [25, 26] , which reacts fully with intact GIP and the N-terminally truncated metabolite. The glucagon assay is directed against the C-terminal (antibody 4305, produced in house) and measures glucagon of mainly pancreatic origin [27] [28] [29] . Plasma insulin and Cpeptide were measured using the Autodelphia automatic fluoroimmunoassay (Wallac, Turku, Finland). Proinsulin was analysed using a two-site enzyme-linked immunoadsorbent assay based on two monoclonal antibodies [30] .
Calculations and statistical analysis All results are expressed as mean±SEM. AUCs were calculated using the trapezoidal rule and are presented as total or incremental values (baseline values subtracted), as indicated. Incretin effects were calculated by the following formula: 100×(incremental [i] AUC) during OGTT-iAUC during i.v. glucose infusion)/ iAUC during OGTT. Insulin secretion rate (ISR) was calculated by deconvolution of plasma C-peptide and application of population-based variables for C-peptide kinetics [31] . ISR is expressed as pmol kg −1 min −1 . Insulin resistance was estimated by the Matsuda index, which is calculated using only values obtained from the OGTT [32] .
We estimated beta cell glucose sensitivity based on the relationship between ISR and glucose levels during the three tests. The calculated ISR was plotted against PG to establish the dose-response relationship (beta cell glucose sensitivity) for each individual on each experimental day, and the slopes of these linear relations during the upstroke phase of the insulin response were expressed as pmol kg
We used this variable to estimate the potentiating effect of the incretin hormones, i.e. a measure of the dynamic 'incretin effect', by calculating the ratio of beta cell glucose sensitivity during the OGTT to the i.v. glucose infusion. In addition, we calculated the 'beta cell index', i.e. the ratio of iAUC ISR to iAUC Glucose during the 240 min (iAUC ISR /iAUC Glucose ). Wilcoxon's test was used for within-group differences and Mann-Whitney U test for between-group differences because of the non-normal distribution of the data. Our power calculation before undertaking the study (power of 80%) indicated that a 25% change in incretin effect required eight participants to achieve statistical significance at the 5% level (two-sided paired t test). However, because of the nonnormal distribution, the less powerful Wilcoxon test had to be used, but the approximate 20% decrease in incretin effect in the NGT group reached statistical significance. Linear regression analysis was performed using standard methods. A p value<0.05 was considered statistically significant.
Results
Glucose Fasting PG (FPG) concentrations were similar on all three experimental days before and after dexamethasone in the two groups. Dexamethasone increased FPG in both the NGT (5.0±0.06 vs 5.3±0.12 mmol/l, p<0.05) and IGT (5.1±0.07 vs 5.7±0.10 mmol/l) groups (p<0.05 for the increase in FPG in both groups); p<0.05 for the difference between the two groups after treatment.
The glucose curves on the OGTT and i.v. glucose infusion days were similar (isoglycaemia) before and after dexamethasone (Fig. 1a-d) . AUC during the OGTT and i.v. glucose infusion increased significantly in both groups after treatment (p<0.05), and during the mixed meal in IGT (Table 2 ). There were no significant differences between groups before dexamethasone during any of the tests. However, after dexamethasone, the AUC increased significantly in the IGT compared with the NGT group in all tests (p<0.05). The iAUC increased significantly in both groups during OGTT and the i.v. glucose infusion. There were no differences in iAUC between the groups for any test. That a difference was found between groups using total AUC and not iAUC is related to the differences in FPG values.
The total amounts of glucose infused in NGT vs IGT were 28.1±2.2 vs 36.0±2.2 g (p<0.05) before and 44.2±3.0 vs 64.1±3.9 g after (p<0.05) dexamethasone.
Total GLP-1 Plasma GLP-1 levels are presented in Figs 2 ad and 4a-d. There were no baseline differences before (NGT 30±3.8 vs IGT 27±2.6 pmol/l) or after (NGT 27±1.7 vs IGT 29±1.0 pmol/l) dexamethasone. There were no significant differences between groups regarding AUCs of any of the tests before or after treatment with dexamethasone. The AUCs increased numerically in both groups during all three Table 2 ). The iAUC did not change significantly in either group in any test after dexamethasone, and there were no significant differences between groups in any tests before or after dexamethasone. The differences observed between incremental and total values are related to the increase seen in fasting GLP-1.
Total GIP There were no baseline differences in fasting GIP between the three experimental days in the two groups, either before or after dexamethasone (Figs 2 e-h and 4e-h). Within each group, there was a highly significant increase in fasting values from 9.1±1.0 to 14±1.2 pmol/l (p<0.001) in the NGT group and from 11±1.1 to 29±5.5 pmol/l after dexamethasone (p<0.001) in the IGT group. There were no significant differences in total AUC or iAUC between groups in any of the tests ( Table 2 ). The AUCs increased significantly in both groups in all three tests after dexamethasone whereas iAUCs only increased significantly in the NGT group during the OGTT and the mixed meal.
Insulin, C-peptide and ISR Fasting insulin, C-peptide and ISR values did not differ between groups on the three experimental days before dexamethasone (Figs 1e-h and i-l and 3e-h and i-j)
. All three variables increased in both groups after treatment (p<0.05), but to a greater extent in the IGT group compared with the NGT group (p<0.05).
The iAUC for insulin, C-peptide and ISR were greater in both groups during OGTT compared with i.v. glucose infusion both before and after dexamethasone (p<0.05; Table 3 ). The iAUCs increased two-to threefold after dexamethasone in both groups during oral and i.v. glucose (p<0.05), but did not differ significantly between the two groups (Table 3) . During the mixed meal, the insulin, C-peptide and ISR responses increased significantly in both groups after dexamethasone, but the responses were similar in the two groups both before and after dexamethasone (Table 3) .
Incretin effects The incretin effect, calculated from insulin iAUC, was 71±3.2% and 67±4.6% before (p00.4) and 58± 5.2% and 32±8.8% after treatment (p<0.05), in the NGT and IGT groups, respectively (Table 3) . In both groups, the incretin effect was reduced after dexamethasone (p<0.05). The incretin effect, calculated from C-peptide or ISR, was smaller compared with that calculated from insulin, but with concordant changes (Table 3 ). The dynamic 'incretin effect' estimated by beta cell glucose sensitivity during oral and i.v. glucose was 2.6±0.33 (NGT) and 2.1±0.31 (IGT) (p00.3) before, and decreased to 1.6±0.22 and 1.4±0.10 (p00.057), respectively, after dexamethasone. The decrease was significant in both groups (p<0.05).
Matsuda index The Matsuda index before treatment was 8.4±1.2 (NGT) and 6.2±0.90 (IGT) (p00.12). After dexamethasone, the Matsuda index decreased significantly in both groups (p<0.05) to 3.6±0.62 and 2.6±0.19, respectively (p00.14). The decrease in Matsuda index did not differ between groups (p00.3)
Proinsulin/C-peptide ratio The proinsulin/C-peptide ratios were similar at baseline, but increased after dexamethasone from 1.4±0.14 to 2.3±0.30 (p<0.05) in the NGT group and from 1.7±0.18 to 3.9±0.56 (p<0.05) in the IGT group, being significantly higher in IGT than in NGT (p<0.05).
Indices of beta cell function during i.v. glucose The beta cell glucose sensitivity to i.v. glucose was similar in the two groups before dexamethasone, and increased by approximately 100% in NGT and 40% in IGT after dexamethasone (p<0.05; Table 3 ). D I(Glucose sensitivity) to i.v. glucose did not differ between the groups before dexamethasone. After treatment D I(Glucose sensitivity) decreased significantly in both groups, and was significantly more reduced in the IGT group compared with the NGT group (p<0.05; Table 3 ).
The beta cell index increased numerically in both groups after dexamethasone, but only significantly in the NGT group. It was similar in the two groups before but significantly smaller in IGT compared with NGT after dexamethasone (Table 3) . D I(Beta cell index) did not differ between the groups before dexamethasone. D I(Beta cell index) decreased significantly in IGT after dexamethasone and was significantly smaller compared with NGT (p<0.05; Table 3 ).
Indices of beta cell function during OGTT The beta cell glucose sensitivity during OGTT (Table 3) illustrates the potentiating effect of the incretin hormones when compared with beta cell glucose sensitivity during i.v. glucose. The beta cell glucose sensitivity during OGTT did not differ before dexamethasone. After treatment, beta cell glucose sensitivity increased significantly in the NGT group, while the absence of an increase in the IGT group is in accordance with the severely reduced incretin effect ( Table 3 ). The D I(Glucose sensitivity) during OGTT was significantly lower in the IGT group before and decreased significantly in both groups after dexamethasone, and was significantly lower in the IGT group compared with the NGT group after dexamethasone (Table 3) .
The beta cell index was similar during OGTT in the two groups before, but significantly lower in IGT compared with NGT after dexamethasone ( Table 3 ). The D I(Beta cell index) during OGTT did not differ between the groups before treatment. After treatment, a significant reduction was observed in both groups, with a significantly lower D I(Beta cell index) in the IGT group compared with the NGT group ( Table 3) .
Indices of beta cell function during mixed meal During the mixed meal, the beta cell glucose sensitivity and beta cell index did not differ significantly between groups before and after dexamethasone (Table 3 ). The D I(Glucose sensitivity) was numerically reduced in both groups after dexamethasone but only significantly in the IGT group, and was significantly lower in IGT compared with NGT (p<0.05, Table 3 ). D I(Beta cell index) decreased significantly only in IGT after dexamethasone, and was significantly lower after treatment in IGT compared with NGT (Table 3) . When comparing the mixed meal and OGTT, the D I(Glucose sensitivity) was greater during the mixed meal in both groups both before and after dexamethasone (p<0.05, Table 3 ). D I(Beta cell index) was also numerically greater when comparing the OGTT and mixed meal, but this failed to reach statistical significance, except for IGT after dexamethasone (Table 3) .
Glucagon Fasting plasma glucagon increased significantly in both groups after treatment (NGT, from 8.1±0.54 to 12.3± 1.04 pmol/l; IGT, from 9.6±0.66 to 14.0±0.91 pmol/l) (p< 0.05) (Figs 2i-l and 4i-l), with no difference between groups. The AUC and iAUC did not differ between groups during any test before treatment (Table 3) . After dexamethasone, the iAUC decrement after OGTT and i.v. glucose increased in both NGT and IGT (Table 3 ). The suppression of glucagon was slightly but insignificantly delayed during the first 45 min during oral compared with i.v. glucose in the NGT group, while in the IGT group the glucagon suppression was significantly greater during i.v. glucose compared with OGTT (p< 0.05). This was mainly due to a significant (p<0.05) delay in glucagon suppression during the first 120 min during OGTT (Fig. 2k-l) . The AUC increased significantly in all tests except in the NGT group during OGTT, which probably represents a type II error. The AUC during the mixed meal increased significantly in both groups, with no significant differences between groups in any tests using AUC.
Discussion
In the current study, we confirm that the incretin effect is intact in healthy first-degree relatives of type 2 diabetes patients, amounting to approximately 70%, as previously observed [34] . However, the incretin effect was reduced when insulin resistance increased, even while normal glucose tolerance was maintained. When our participants developed glucose intolerance in addition to insulin resistance, we observed a further, significant, decline in the incretin effect. As the increase in insulin resistance in the two groups was identical, our results suggest that insulin resistance and glucose intolerance contribute as separate factors to the reduced incretin effect in patients with type 2 diabetes. Even though our study design per se does not allow us to conclude that the reduced incretin effect observed is a consequence and not a cause of the declining glucose tolerance, previous studies [11, 35] from our group have addressed this question, and together the evidence supports the former. The mechanistic explanation for the impaired incretin effect in our study does not involve a reduced secretion of the two incretin hormones GLP-1 and GIP (measured as total hormones to capture all changes in secretion, independent of possible variations in dipeptidyl peptidase-4 (DPP-4) activity [36] ) as neither GLP-1 nor GIP secretion decreased during OGTT after dexamethasone. Therefore, the present results indicate that the decline in the incretin effect is due to a loss of the insulinotropic properties of the two incretin hormones, which is most pronounced in the IGT group. A previous study in a population without genetic disposition to type 2 diabetes similarly found that steroid treatment did not change the overall secretion of GLP-1 but led to an increase in overall secretion of GIP and glucagon during a mixed meal [37] .
Insulin resistance induced with 5 days of dexamethasone was based on previous studies [13] , which, in agreement with the present study, showed that some individuals treated with dexamethasone developed IGT while the others remained NGT. On the three consecutive test days immediately after the 5 days of dexamethasone the fasting concentrations of glucose and insulin did not increase or decrease from day 1 to 3, suggesting that a steady state, with regard to insulin resistance, had been reached.
In addition to reduced insulin-mediated peripheral glucose disposal [38, 39] , glucocorticoids are also known to reduce oxidative and non-oxidative pathways of glucose disposal [38] , reduce muscle glycogen synthase activity [40] , and to induce hepatic insulin resistance [39] . As such, the insulin resistance induced by glucocorticoids resembles the insulin resistance seen in type 2 diabetes. The NGT group did show a small increase in FPG and AUC Glucose after dexamethasone, but this increase was small indicating that the beta cell could compensate adequately for the increasing insulin resistance.
As beta cell function is a determinant of normal or abnormal glucose tolerance, we calculated indices of beta cell function. The proinsulin/C-peptide ratio is a sensitive index of beta cell dysfunction, and has been reported to predict the risk of type 2 diabetes in individuals with NGT [41] , increasing progressively as beta cell function decreases and glycaemia increases [42] . The proinsulin/C-peptide ratio increased after dexamethasone in both groups, but more marked in the IGT group. The increase in the ratio may reflect the increased demand for insulin, forcing the beta cell to secrete immature granules with a high content of proinsulin, as previous reported by Kahn et al [43] .
The insulin response to i.v. glucose is impaired early in the development of type 2 diabetes, and is one of the factors determining the progression from normal to abnormal glucose tolerance [44] . Beta cell glucose sensitivity is an integrated measure of glucose-induced insulin secretion over hours, and was significantly impaired in the IGT group, with an approximately 40% decrease after dexamethasone when corrected for insulin resistance by calculation of the D I(Glucose sensitivity) ; the decrease was numerically lower in the NGT group, and failed to reach statistical significance. The third index we calculated, D I(Beta cell index) , decreased significantly in the IGT group. Taken together, the results indicate that the reduced incretin effect is an early phenomenon in the development of type 2 diabetes, which is, in part, due to a general beta cell dysfunction. It was observed in people with preserved NGT, and in whom the proinsulin/C-peptide ratio was significantly increased, and the D I(Beta cell index) and D I(Glucose sensitivity) were not significantly reduced. Along with the progressive impairment in the incretin effect in the group developing IGT, parallel statistically significant reductions in D I(Glucose sensitivity) and D I(Beta cell index) were observed, indicating a more severe global beta cell dysfunction.
The beta cell glucose sensitivity to oral glucose was greater in both groups compared with i.v. glucose before dexamethasone, and in the NGT group after dexamethasone, in accordance with the potentiation of insulin secretion by the incretin hormones. In the participants with IGT, the beta cell glucose sensitivity did not differ significantly during the i.v. glucose and OGTT, in accordance with the severe impairment of the incretin effect in this group after dexamethasone. Interestingly, during the mixed meal, where insulin secretion is stimulated not only by the incretin hormones but also by non-glucose substrates and neurotransmitters, the beta cell glucose sensitivity and the beta cell index were numerically greater compared with oral glucose, except for the beta cell index in NGT after dexamethasone, which was similar. This indicates a greater potentiation of glucoseinduced insulin release by mixed-meal stimulation than by OGTT, where primarily the incretin hormones and glucose stimulate insulin release.
Recently, it has been argued [45] that the maximal secretory capacity of the beta cells is reached during the IVGTT of isoglycaemic challenges for the study of incretin effect in type 2 diabetes, meaning that the incretin hormones cannot further increase insulin secretion on oral stimulation, which could explain the apparent loss of the incretin effect. However, in our participants with NGT, this is unlikely to be the cause of the reduced incretin effect, particularly as the beta cell response to the mixed meal was significantly greater than to i.v. glucose after glucocorticoid treatment. In addition, other studies showed that supraphysiological concentrations of GLP-1 dramatically increased glucose-induced insulin secretion in type 2 diabetes [10, 46] .
Regarding glucagon, we found that the increase in insulin resistance was associated with an inappropriate large increase in glucagon secretion. This is of interest because an increase in glucagon secretion is an important diabetogenic factor in type 2 diabetes. Alpha cell dysfunction must therefore be included among the diabetogenic effects of glucocorticoids. Furthermore, the increase in both groups point to alpha cell dysfunction as a very early sign in diabetes development. A delayed glucagon suppression during OGTT, as seen here in the IGT group after dexamethasone, has also been observed in type 2 diabetes [47] .
